Combination of CT/MRI LI-RADS With Second-Line Contrast-Enhanced Ultrasound Using Sulfur Hexafluoride or Perfluorobutane for Diagnosing Hepatocellular Carcinoma in High-Risk Patients.

IF 4.4 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Korean Journal of Radiology Pub Date : 2025-04-01 Epub Date: 2025-02-20 DOI:10.3348/kjr.2024.0980
Yu Li, Sheng Li, Qing Li, Kai Li, Jing Han, Siyue Mao, Xiaohong Xu, Zhongzhen Su, Yanling Zuo, Shousong Xie, Hong Wen, Xuebin Zou, Jingxian Shen, Lingling Li, Jianhua Zhou
{"title":"Combination of CT/MRI LI-RADS With Second-Line Contrast-Enhanced Ultrasound Using Sulfur Hexafluoride or Perfluorobutane for Diagnosing Hepatocellular Carcinoma in High-Risk Patients.","authors":"Yu Li, Sheng Li, Qing Li, Kai Li, Jing Han, Siyue Mao, Xiaohong Xu, Zhongzhen Su, Yanling Zuo, Shousong Xie, Hong Wen, Xuebin Zou, Jingxian Shen, Lingling Li, Jianhua Zhou","doi":"10.3348/kjr.2024.0980","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The CT/MRI Liver Imaging Reporting and Data System (LI-RADS) demonstrates high specificity with relatively limited sensitivity for diagnosing hepatocellular carcinoma (HCC) in high-risk patients. This study aimed to explore the possibility of improving sensitivity by combining CT/MRI LI-RADS v2018 with second-line contrast-enhanced ultrasound (CEUS) LI-RADS v2017 using sulfur hexafluoride (SHF) or perfluorobutane (PFB).</p><p><strong>Materials and methods: </strong>This retrospective analysis of prospectively collected multicenter data included high-risk patients with treatment-naive hepatic observations. The reference standard was pathological confirmation or a composite reference standard (only for benign lesions). Each participant underwent concurrent CT/MRI, SHF-enhanced US, and PFB-enhanced US examinations. The diagnostic performances for HCC of CT/MRI LI-RADS alone and three combination strategies (combining CT/MRI LI-RADS with either LI-RADS SHF, LI-RADS PFB, or a modified algorithm incorporating the Kupffer-phase findings for PFB [modified PFB]) were evaluated. For the three combination strategies, apart from the CT/MRI LR-5 criteria, HCC was diagnosed if CT/MRI LR-3 or LR-4 observations met the LR-5 criteria using LI-RADS SHF, LI-RADS PFB, or modified PFB.</p><p><strong>Results: </strong>In total, 281 participants (237 males; mean age, 55 ± 11 years) with 306 observations (227 HCCs, 40 non-HCC malignancies, and 39 benign lesions) were included. Using LI-RADS SHF, LI-RADS PFB, and modified PFB, 20, 23, and 31 CT/MRI LR-3/4 observations, respectively, were reclassified as LR-5, and all were pathologically confirmed as HCCs. Compared to CT/MRI LI-RADS alone (74%, 95% confidence interval [CI]: 68%-79%), the three combination strategies combining CT/MRI LI-RADS with either LI-RADS SHF, LI-RADS PFB, or modified PFB increased sensitivity (83% [95% CI: 77%-87%], 84% [95% CI: 79%-89%], 88% [95% CI: 83%-92%], respectively; all <i>P</i> < 0.001), while maintaining the specificity at 92% (95% CI: 84%-97%).</p><p><strong>Conclusion: </strong>The combination of CT/MRI LI-RADS with second-line CEUS using SHF or PFB improved the sensitivity of HCC diagnosis without compromising specificity.</p>","PeriodicalId":17881,"journal":{"name":"Korean Journal of Radiology","volume":" ","pages":"346-359"},"PeriodicalIF":4.4000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955382/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Korean Journal of Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3348/kjr.2024.0980","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/20 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The CT/MRI Liver Imaging Reporting and Data System (LI-RADS) demonstrates high specificity with relatively limited sensitivity for diagnosing hepatocellular carcinoma (HCC) in high-risk patients. This study aimed to explore the possibility of improving sensitivity by combining CT/MRI LI-RADS v2018 with second-line contrast-enhanced ultrasound (CEUS) LI-RADS v2017 using sulfur hexafluoride (SHF) or perfluorobutane (PFB).

Materials and methods: This retrospective analysis of prospectively collected multicenter data included high-risk patients with treatment-naive hepatic observations. The reference standard was pathological confirmation or a composite reference standard (only for benign lesions). Each participant underwent concurrent CT/MRI, SHF-enhanced US, and PFB-enhanced US examinations. The diagnostic performances for HCC of CT/MRI LI-RADS alone and three combination strategies (combining CT/MRI LI-RADS with either LI-RADS SHF, LI-RADS PFB, or a modified algorithm incorporating the Kupffer-phase findings for PFB [modified PFB]) were evaluated. For the three combination strategies, apart from the CT/MRI LR-5 criteria, HCC was diagnosed if CT/MRI LR-3 or LR-4 observations met the LR-5 criteria using LI-RADS SHF, LI-RADS PFB, or modified PFB.

Results: In total, 281 participants (237 males; mean age, 55 ± 11 years) with 306 observations (227 HCCs, 40 non-HCC malignancies, and 39 benign lesions) were included. Using LI-RADS SHF, LI-RADS PFB, and modified PFB, 20, 23, and 31 CT/MRI LR-3/4 observations, respectively, were reclassified as LR-5, and all were pathologically confirmed as HCCs. Compared to CT/MRI LI-RADS alone (74%, 95% confidence interval [CI]: 68%-79%), the three combination strategies combining CT/MRI LI-RADS with either LI-RADS SHF, LI-RADS PFB, or modified PFB increased sensitivity (83% [95% CI: 77%-87%], 84% [95% CI: 79%-89%], 88% [95% CI: 83%-92%], respectively; all P < 0.001), while maintaining the specificity at 92% (95% CI: 84%-97%).

Conclusion: The combination of CT/MRI LI-RADS with second-line CEUS using SHF or PFB improved the sensitivity of HCC diagnosis without compromising specificity.

CT/MRI LI-RADS联合六氟化硫或全氟丁烷二级增强超声诊断高危患者肝细胞癌
目的:CT/MRI肝脏影像报告与数据系统(LI-RADS)对高危患者肝细胞癌(HCC)的诊断具有高特异性和相对有限的敏感性。本研究旨在探讨使用六氟化硫(SHF)或全氟丁烷(PFB),将CT/MRI LI-RADS v2018与二线对比增强超声(CEUS) LI-RADS v2017结合使用,提高灵敏度的可能性。材料和方法:回顾性分析前瞻性收集的多中心数据,包括未接受治疗的肝脏观察的高危患者。参考标准为病理确认或复合参考标准(仅适用于良性病变)。每位参与者同时接受CT/MRI、shf增强超声和pfb增强超声检查。评估了CT/MRI LI-RADS单独和三种组合策略(将CT/MRI LI-RADS与LI-RADS SHF、LI-RADS PFB或结合PFB的Kupffer-phase结果的改进算法相结合)对HCC的诊断性能。对于三种联合策略,除了CT/MRI LR-5标准外,如果CT/MRI LR-3或LR-4观察结果符合LI-RADS SHF, LI-RADS PFB或改良PFB的LR-5标准,则诊断为HCC。结果:共281名参与者(237名男性;平均年龄(55±11岁),306例观察(227例hcc, 40例非hcc恶性病变,39例良性病变)。使用LI-RADS SHF、LI-RADS PFB和改良PFB,分别将20、23和31例CT/MRI LR-3/4观察结果重新分类为LR-5,病理证实均为hcc。与单独使用CT/MRI LI-RADS相比(74%,95%可信区间[CI]: 68%-79%),将CT/MRI LI-RADS与LI-RADS SHF、LI-RADS PFB或改良PFB联合使用的三种组合策略分别提高了敏感性(83% [95% CI: 77%-87%]、84% [95% CI: 79%-89%]、88% [95% CI: 83%-92%];均P < 0.001),而特异性维持在92% (95% CI: 84%-97%)。结论:CT/MRI LI-RADS联合使用SHF或PFB的二线超声造影提高了HCC诊断的敏感性,但不影响特异性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Korean Journal of Radiology
Korean Journal of Radiology 医学-核医学
CiteScore
10.60
自引率
12.50%
发文量
141
审稿时长
1.3 months
期刊介绍: The inaugural issue of the Korean J Radiol came out in March 2000. Our journal aims to produce and propagate knowledge on radiologic imaging and related sciences. A unique feature of the articles published in the Journal will be their reflection of global trends in radiology combined with an East-Asian perspective. Geographic differences in disease prevalence will be reflected in the contents of papers, and this will serve to enrich our body of knowledge. World''s outstanding radiologists from many countries are serving as editorial board of our journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信